Gene: CISH
Official Full Name: cytokine inducible SH2 containing proteinprovided by HGNC
Gene Summary: The protein encoded by this gene contains a SH2 domain and a SOCS box domain. The protein thus belongs to the cytokine-induced STAT inhibitor (CIS), also known as suppressor of cytokine signaling (SOCS) or STAT-induced STAT inhibitor (SSI), protein family. CIS family members are known to be cytokine-inducible negative regulators of cytokine signaling. The expression of this gene can be induced by IL2, IL3, GM-CSF and EPO in hematopoietic cells. Proteasome-mediated degradation of this protein has been shown to be involved in the inactivation of the erythropoietin receptor. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO11323 | CISH Knockout cell line (HeLa) | Human | CISH | 1:3~1:6 | Negative | Online Inquiry |
KO11324 | CISH Knockout cell line (HCT 116) | Human | CISH | 1:2~1:4 | Negative | Online Inquiry |
KO11325 | CISH Knockout cell line (HEK293) | Human | CISH | 1:3~1:6 | Negative | Online Inquiry |
CISH Gene Knockout Cell Lines are engineered cell lines that have had the Cytokine Inducible SH2-containing protein (CISH) gene inactivated, allowing researchers to explore the role of CISH in various cellular processes. This strategic genetic modification facilitates the study of signaling pathways and immune responses, particularly those involving the Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathways, which are critical in hematopoiesis and immune function.
The primary mechanism through which CISH exerts its function is by acting as a negative regulator of cytokine signaling. By binding to activated JAKs, CISH inhibits downstream signaling cascades, thus modulating how cells respond to cytokines. This makes CISH Gene Knockout Cell Lines an invaluable tool in dissecting the nuances of cytokine signaling and its implications in diseases, including autoimmune disorders and cancers.
In research and clinical settings, these cell lines are pivotal for understanding the pathophysiology of various diseases and developing targeted therapies. For instance, the ablation of the CISH gene may enhance the efficacy of certain cytokine therapies, offering a promising avenue for treating conditions where cytokine signaling is dysregulated.
What sets our CISH Gene Knockout Cell Lines apart from alternatives on the market are their optimal validation and high-performance characteristics. Our cell lines are meticulously designed to ensure reliability and reproducibility, which are crucial for producing scientifically robust data. Additionally, we offer comprehensive support and detailed user guidelines, making it easier for researchers and clinicians to integrate these cell lines into their studies.
Investing in our CISH Gene Knockout Cell Lines is an investment in cutting-edge research that promises to unravel the complexities of immune regulation and pave the way for groundbreaking advancements in therapeutic interventions. As a company with a strong focus on innovation and quality in biological products, we remain committed to delivering tools that empower and enhance scientific discovery.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.